Population Pharmacokinetic Analysis of Mycophenolic Acid in Renal Transplant Recipients Following Oral Administration of Mycophenolate Mofetil

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2003 Aug 5

PMID 12895192

Citations 28

Authors

B Shum

S B Duffull

P J Taylor

S E Tett

Affiliations

Soon will be listed here.

Abstract

Aim: To develop a population pharmacokinetic model for mycophenolic acid in adult kidney transplant recipients, quantifying average population pharmacokinetic parameter values, and between- and within-subject variability and to evaluate the influence of covariates on the pharmacokinetic variability.

Methods: Pharmacokinetic data for mycophenolic acid and covariate information were previously available from 22 patients who underwent kidney transplantation at the Princess Alexandra Hospital. All patients received mycophenolate mofetil 1 g orally twice daily. A total of 557 concentration-time points were available. Data were analysed using the first-order method in NONMEM (version 5 level 1.1) using the G77 FORTRAN compiler.

Results: The best base model was a two-compartment model with a lag time (apparent oral clearance was 27 l h(-1), and apparent volume of the central compartment 98 l). There was visual evidence of complex absorption and time-dependent clearance processes, but they could not be successfully modelled in this study. Weight was investigated as a covariate, but no significant relationship was determined.

Conclusions: The complexity in determining the pharmacokinetics of mycophenolic acid is currently underestimated. More complex pharmacokinetic models, though not supported by the limited data collected for this study, may prove useful in the future. The large between-subject and between-occasion variability and the possibility of nonlinear processes associated with the pharmacokinetics of mycophenolic acid raise questions about the value of the use of therapeutic monitoring and limited sampling strategies.

Citing Articles

Population pharmacokinetic analysis identifies an absorption process model for mycophenolic acid in patients with renal transplant.

Suzuki Y, Matsunaga N, Aoyama T, Ogami C, Hasegawa C, Iida S Clin Transl Sci. 2024; 17(12):e70097.

PMID: 39629510 PMC: 11615510. DOI: 10.1111/cts.70097.

Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis.

Mizaki T, Nobata H, Banno S, Yamaguchi M, Kinashi H, Iwagaitsu S J Pharm Health Care Sci. 2023; 9(1):1.

PMID: 36624529 PMC: 9830922. DOI: 10.1186/s40780-022-00271-w.

Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis.

Ameijeiras Rodriguez C, Henriques S, Sancho-Araiz A, Troconiz I, Almeida L, Silva N Pharm Res. 2021; 38(12):2047-2063.

PMID: 34932170 DOI: 10.1007/s11095-021-03136-3.

Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients.

Rong Y, Mayo P, Ensom M, Kiang T Clin Pharmacokinet. 2019; 58(11):1483-1495.

PMID: 31055791 DOI: 10.1007/s40262-019-00771-3.

Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure.

Okour M, Jacobson P, Ahmed M, Israni A, Brundage R J Clin Pharmacol. 2018; 58(5):628-639.

PMID: 29329489 PMC: 5910266. DOI: 10.1002/jcph.1064.

References

Johnson A, Rigby R, Taylor P, Jones C, Allen J, Franzen K . The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther. 1999; 66(5):492-500. DOI: 10.1016/S0009-9236(99)70012-3. View

Hubner G, Eismann R, Sziegoleit W . Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit. 1999; 21(5):536-9. DOI: 10.1097/00007691-199910000-00008. View

Filler G, Mai I . Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit. 2000; 22(2):169-73. DOI: 10.1097/00007691-200004000-00005. View

Mele T, Halloran P . The use of mycophenolate mofetil in transplant recipients. Immunopharmacology. 2000; 47(2-3):215-45. DOI: 10.1016/s0162-3109(00)00190-9. View

Willis C, Taylor P, Salm P, Tett S, Pillans P . Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients. Ther Drug Monit. 2000; 22(5):549-54. DOI: 10.1097/00007691-200010000-00008. View

Shaw L, Korecka M, DeNofrio D, Brayman K . Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem. 2001; 34(1):17-22. DOI: 10.1016/s0009-9120(00)00184-3. View

Pillans P, Rigby R, Kubler P, Willis C, Salm P, Tett S . A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem. 2001; 34(1):77-81. DOI: 10.1016/s0009-9120(00)00196-x. View

van Gelder T, Klupp J, Barten M, Christians U, Morris R . Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001; 23(2):119-28. DOI: 10.1097/00007691-200104000-00005. View

Mourad M, Malaise J, Chaib Eddour D, De Meyer M, Konig J, Schepers R . Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem. 2001; 47(7):1241-8. View

10.

Wahlby U, Jonsson E, Karlsson M . Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001; 28(3):231-52. DOI: 10.1023/a:1011527125570. View

11.

Shaw L, Holt D, Oellerich M, Meiser B, van Gelder T . Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001; 23(4):305-15. DOI: 10.1097/00007691-200108000-00001. View

12.

Shaw L, Pawinski T, Korecka M, Nawrocki A . Monitoring of mycophenolic acid in clinical transplantation. Ther Drug Monit. 2002; 24(1):68-73. DOI: 10.1097/00007691-200202000-00012. View

13.

Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G . Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002; 62(3):1060-7. DOI: 10.1046/j.1523-1755.2002.00531.x. View

14.

. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet. 1995; 345(8961):1321-5. View

15.

Nowak I, Shaw L . Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995; 41(7):1011-7. View

16.

Sollinger H . Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995; 60(3):225-32. DOI: 10.1097/00007890-199508000-00003. View

17.

Ransom J . Mechanism of action of mycophenolate mofetil. Ther Drug Monit. 1995; 17(6):681-4. DOI: 10.1097/00007691-199512000-00023. View

18.

Bullingham R, Nicholls A, Hale M . Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc. 1996; 28(2):925-9. View

19.

. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1996; 61(7):1029-37. View

20.

Hood K, Zarembski D . Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm. 1997; 54(3):285-94. DOI: 10.1093/ajhp/54.3.285. View